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Thrombophilia in pregnancy: a systematic review
Thrombotic mechanisms underlie many pregnancy complica-
tions. Pulmonary embolism (PE), arising from deep-vein
thrombosis (DVT) is the leading cause of maternal death in
the UK (Department of Health Welsh Office Scottish Home
and Health Department and Department of Health and Social
Services Northern Ireland, 1998). It is now clear that both
heritable and acquired thrombophilias are associated with
many thrombotic events in pregnancy. The major heritable
forms of thrombophilia include deficiencies of antithrombin,
protein C and protein S, abnormalities of procoagulant factors,
particularly, factor V Leiden and the prothrombin G20210A
gene polymorphisms. Furthermore, homozygosity for methyl-
enetetrahydrofolate reductase (MTHFR) C677T can be associ-
ated with hyperhomocysteinaemia, which is, in turn, associated
with increased risk of vascular events. The most common
acquired thrombophilias are antiphospholipids, which com-
prise lupus inhibitors and anticardiolipin antibodies.
There is growing evidence that women with thrombophilia
are at increased risk, not only of pregnancy-related venous
thromboembolism (VTE), but also other vascular pregnancy
complications, including fetal loss, pre-eclampsia and intra-
uterine growth restriction (IUGR) (Walker, 2000a). One of the
early reports found that 65% of women with pre-eclampsia,
IUGR, unexplained stillbirth or placental abruption had a form
of heritable or acquired thrombophilia (Kupferminc et al,
1999). Many studies have now examined the association
between thrombophilia and pregnancy complications, often
with differing results. Although several reviews of thrombo-
embolic disease in pregnancy and thromboprophylaxis have
been published, many have methodological limitations or
focus on a particular pregnancy complication, such as
recurrent pregnancy loss or a particular thrombophilia, such
as factor V Leiden (Gates, 2000; Walker, 2000b; Alfirevic et al,
2002; Empson et al, 2002; Ghee & Burrows, 2002; Morrison
L. Robertson,1 O. Wu,1 P. Langhorne,1
S. Twaddle,2 P. Clark,3 G. D. O. Lowe,1,2
I. D. Walker,1 M. Greaves,4 I. Brenkel,5
L. Regan6 and I. A. Greer1 for The
Thrombosis: Risk and Economic
Assessment of Thrombophilia Screening
(TREATS) Study.
1Departments of Obstetrics and Gynaecology and
Medicine, University of Glasgow, Glasgow,
2Scottish Intercollegiate Guidelines Network,
Edinburgh, 3Ninewells Hospital, Dundee,
4Department of Medicine and Therapeutics,
University of Aberdeen, Aberdeen, 5Fife Acute
Hospital NHS Trust, and 6Department of
Obstetrics and Gynaecology, Imperial College
School of Medicine, London, UK
Received 2 August 2005; accepted for
publication 12 September 2005
Correspondence: Professor Ian Greer,
Reproductive and Maternal Medicine, Division
of Developmental Medicine, University of
Glasgow, Glasgow Royal Infirmary, 10
Alexandra Parade, Glasgow G31 2ER, UK.
E-mail: ian.a.greer@clinmed.gla.ac.uk
Summary
Growing evidence suggests that thrombophilia is associated with venous
thromboembolism (VTE) and adverse pregnancy outcomes. However,
methodological limitations have made it difficult to obtain a clear overview
of the overall risks. We conducted a systematic review to determine the risk of
VTE and adverse pregnancy outcomes associated with thrombophilia in
pregnancy. The effectiveness of prophylactic interventions during pregnancy
was also evaluated. Major electronic databases were searched, relevant data
abstracted and study quality assessed by two independent reviewers. Odds
ratios (ORs) stratified by thrombophilia type were calculated for each
outcome. A total of 79 studies were included in our review. The risks for
individual thrombophilic defects were determined for VTE (ORs, 0Æ74–
34Æ40); early pregnancy loss (ORs, 1Æ40–6Æ25); late pregnancy loss (ORs, 1Æ31–
20Æ09); pre-eclampsia (ORs, 1Æ37–3Æ49); placental abruption (ORs, 1Æ42–7Æ71)
and intrauterine growth restriction (ORs, 1Æ24–2Æ92). Low-dose aspirin plus
heparin was the most effective in preventing pregnancy loss in thrombophilic
women (OR, 1Æ62). Our findings confirm that women with thrombophilia
are at risk of developing VTE and complications in pregnancy. However,
despite the increase in relative risk, the absolute risk of VTE and adverse
outcomes remains low. There is also a lack of controlled trials of
antithrombotic intervention to prevent pregnancy complications. Thus, at
present, universal screening for thrombophilia in pregnancy cannot be
justified clinically.
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et al, 2002; Greer, 2003; Rey et al, 2003). These methodological
limitations and the fragmentation of publication of the
available data on various thrombophilias and outcomes, has
made it difficult for clinicians to obtain a clear overview of the
overall risks of VTE and adverse pregnancy outcomes in
women with thrombophilia. Thus a comprehensive review of
the risk of heritable and acquired thrombophilias in pregnancy
is required. The objective of this study was to assess the overall
relationship between all major thrombophilias and VTE and
the adverse outcomes of pregnancy loss, pre-eclampsia, IUGR
and abruption. Furthermore the available data on prophylactic
intervention in this situation were also evaluated.
Methods
Searching
An extensive literature search was carried out by two
independent reviewers on all major electronic databases:
Medline 1996 to June 2003, BIDS (EMBASE) 1980 to June
2003, the Cumulative Index to Nursing and Allied Health
Literature print index 1982 to June 2003, Cochrane Database
of Systematic Reviews 1998 to June 2003, Database of Reviews
of Effectiveness 1995 to June 2003 and Kings Fund, UK (last
accessed June 2003). Relevant keywords relating to thrombo-
philia, VTE and adverse pregnancy outcomes were combined
with established search filters for randomised controlled trials
and observational studies (NHS Centre for Review &
Dissemination, 2001) to capture all potentially relevant studies.
Only articles published in English were retrieved. In addition,
hand searching the abstracts of recent thrombosis conferences
and the references of all studies meeting the reference criteria
were also carried out.
Inclusion and exclusion criteria
Studies were included in the review if they met the
following criteria: (i) study population included women
with one or more identified thrombophilia who were
pregnant or up to 6-week postpartum; (ii) clinical outcomes
included incidence of VTE events and/or adverse pregnancy
outcomes were recorded; (iii) extractable data that defined
categorically the presence or absence of any thrombophilic
defects were available; and (iv) study design described as
randomised controlled trials, prospective observational stud-
ies or retrospective observational studies. Studies with cases
selected on the basis of autoimmune disease, studies
without controls or with control groups that included
men or current users of hormonal contraceptives were
excluded.
Data abstraction and quality assessment
Data extraction was carried out independently by two inves-
tigators using pre-piloted data extraction forms, and the
quality of the studies was also assessed. Major study outcomes
included all VTE and adverse pregnancy incidences. Venous
thromboembolism events included all objectively diagnosed
DVT and PE events. Adverse pregnancy outcomes including
early pregnancy loss (spontaneous loss in the first or second
trimester), late pregnancy loss (spontaneous loss in the third
trimester), pre-eclampsia (diastolic blood pressure ‡90 mmHg
plus proteinuria; Walker, 2000b), placental abruption, IUGR
(birth weight below the 10th centile for gestational age), and
postpartum haemorrhage (defined as minor if blood loss was
500–1500 ml and major if blood loss was >1500 ml after
childbirth) (Scottish Obstetric Guidelines and Audit Project,
1998).
To evaluate the effectiveness of prophylactic interventions in
pregnant women with thrombophilia in the prevention of
recurrent pregnancy loss, all the data relating to pharmacolo-
gical and non-pharmacological prophylactic interventions
were extracted for analysis. These include: unfractionated
heparin, low molecular weight (LMW) heparins, warfarin,
aspirin, dextran, recombinant hirudin, plaquinil, calf com-
pression, foot pumps and compression stockings. In addition,
data on adverse drug reactions including haemorrhage, serious
wound complications, thrombocytopenia and osteoporotic
fractures were also extracted if available.
This review has been designed to summarise clinical
evidence across study types, therefore, a single checklist,
adapted from quality checklists recommended by the Centre
for Review and Dissemination was used (NHS Centre for
Review & Dissemination, 2001). Seven major criteria were
assessed including representative inception cohort, appropriate
comparator group, blinded assessment of outcomes, adjust-
ment for confounding, appropriate follow-up and description
of cohorts. Any disagreement between the reviewers was
resolved by discussion.
Analysis
Odds ratios (ORs) for each clinical outcome per woman
were calculated and stratified by individual thrombophilic
defects. For the purpose of our review, data relating to the
first and second trimester losses were aggregated to deter-
mine the overall risk of early pregnancy loss, as some
publications did not provide data on the gestation at loss.
Where possible, the risks of recurrent first trimester and
non-recurrent second trimester loss were calculated sepa-
rately. In addition, the risk of recurrent pregnancy loss was
also summarised according to the use of prophylactic
interventions to determine the relative effectiveness of
different interventions.
Where appropriate, meta-analysis was carried out and
pooled OR were calculated based on the random effects
model (DerSimonian & Laird, 1986), which accounts for
interstudy variation and provides a more conservative effect
than the fixed effect model (NHS Centre for Review &
Dissemination, 2001). Potential sources of heterogeneity
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were assessed using the standard chi-square test. In addition,
the statistic I2 was used to investigate heterogeneity by
examining the extent of inconsistency across the study
results (Higgins et al, 2003). Sensitivity analysis was carried
out to assess the robustness of the results of the meta-
analysis. Where heterogeneity was present between the
studies, differences in study design were examined. All
analyses were performed using RevMan 4.1 (Cochrane
Collaboration, Oxford, UK).
Results
Of the 234 studies located through electronic databases and
hand searching, 79 studies met the inclusion criteria (Fig 1)
(63 case control studies, 13 cohort studies and three random-
ised controlled trials). Data relating to VTE and adverse
pregnancy outcomes were extracted for analysis, but no studies
reported incidents of postpartum haemorrhage. Overall, the
methodological quality of the studies were sound; however, the
major limitation common to most studies was the failure to
identify additional risk factors in the populations studied
(Table I).
VTE
Nine studies (n ¼ 2526) assessed the risk of VTE in
pregnant women with heritable thrombophilia (Grandone
et al, 1998; Dilley et al, 2000; Gerhardt et al, 2000; Murphy
et al, 2000; Pabinger et al, 2000; Martinelli et al, 2001a,
2002; Tormene et al, 2001; Ogunyemi et al, 2003). With the
exception of homozygosity for MTHFR C677T, all heritable
thrombophilias were found to be significantly associated
with an increased risk of VTE (Fig 2). In particular, the OR
for VTE among factor V Leiden homozygous carriers during
pregnancy was as high as 34Æ40 (95% CI 9Æ86–120Æ05)
(Gerhardt et al, 2000; Murphy et al, 2000; Martinelli et al,
2001a; Tormene et al, 2001). The pooled data on MTHFR
homozygous cases indicated significant heterogeneity (Fig 2).
However, women in one of the studies were given folic acid
supplement, which has potential confounding effects on
homocysteine levels and VTE events (Ogunyemi et al, 2003).
This study was excluded when performing the sensitivity
analysis. The remaining studies consisted of two retro-
spec tive case–control (Grandone et al, 1998; Dilley et al,
2000) and one prospective cohort (Murphy et al, 2000)
studies. Meta-analysis of the case–control studies only,
indicated no significant heterogeneity (P ¼ 0Æ49) or incon-
sistency (I2 ¼ 0%) and gave an OR of 1Æ83 (95% CI 0Æ95–
3Æ51).
Early pregnancy loss
Twenty-five studies (n ¼ 7167) evaluated the association
between thrombophilia and early pregnancy loss (Das et al,
1991; Infante-Rivard et al, 1991; Wouters et al, 1993; De
Carolis et al, 1994; Ogasawara et al, 1996; Balasch et al, 1997;
Grandone et al, 1997a; Nelen et al, 1997; Higashino et al,
1998; Chakrabarti et al, 1999; Hatzis et al, 1999; Holmes
et al, 1999; Lissak et al, 1999; Tal et al, 1999; Fatini et al,
2000; Kupferminc et al, 2000a; Pabinger et al, 2000; Younis
et al, 2000; Pickering et al, 2001; Pihusch et al, 2001; Rai
et al, 2001; Raziel et al, 2001; Reznikoff-Etievan et al, 2001;
Carp et al, 2002; Finan et al, 2002), and showed positive
associations overall (Fig 3). In particular, significantly asso-
ciations were observed in carriers of homozygous factor V
Leiden (OR 2Æ71; 95% CI 1Æ32–5Æ58), heterozygous factor V
Leiden (OR 1Æ68; 95% CI 1Æ09–2Æ58), prothrombin hetero-
zygosity (OR 2Æ49; 95% CI 1Æ24–5Æ00), anticardiolipin anti-
bodies (OR 3Æ40; 95% CI 1Æ33–8Æ68), lupus anticoagulants
(OR 2Æ97; 95% CI 1Æ03–8Æ56), acquired APCR (OR 4Æ04; 95%
CI 1Æ67–9Æ76) and hyperhomocysteinaemia (OR 6Æ25; 95% CI
1Æ37–28Æ42) (Fig 3). Significant heterogeneity (P ¼ 0Æ04) and
inconsistency (I2 ¼ 59Æ1%) was observed with the meta-
analysis of lupus anticoagulants; however, this could not be
explained by study design, as all the studies were case–control
studies.
Early pregnancy loss was separated into recurrent preg-
nancy loss in the first trimester and single pregnancy loss in
the second trimester and analysed (Figs 4 and 5). Due to the
limitations of the available data, the analysis on factor V
Leiden incorporates both homozygous and heterozygous
carriers. These women were found to be at higher risk of
pregnancy loss in the second compared with the first
trimester (OR 4Æ12; 95% CI 1Æ93–8Æ81 and OR 1Æ91; 95% CI
1Æ01–3Æ61 respectively) (Grandone et al, 1997a; Tal et al,
1999; Tormene et al, 1999; Foka et al, 2000; Rai et al,Fig 1. Selection of studies for systematic review in pregnancy.
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* Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia.
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Fig 2. Risk of venous thromboembolism (VTE) in woman with thrombophilia. FVL, factor V Leiden; PTM, prothrombin; ATM, antithrombin; PC
def, protein C deficiency; PS def, protein S deficiency. The square on each line represents the point estimate for the odds ratio for each single study; its
size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio and the confidence interval
from pooling all the studies together in the meta-analysis.
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* Data was only available from one study, therefore meta-analysis was not performed for this mutation.
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Fig 3. Risk of early loss in woman with thrombophilia. The square on each line represents the point estimate for the odds ratio for each single study;
its size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio and the confidence interval
from pooling all the studies together in the meta-analysis.
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2001; Reznikoff-Etievan et al, 2001; Carp et al, 2002; Finan
et al, 2002). However, there was evidence of heterogeneity
in the analysis of recurrent first trimester loss (P ¼ 0Æ001);
this could not be explained by the difference in study
design. A similar trend was observed with prothrombin
heterozygosity. The risk of non-recurrent second trimester
loss (OR 8Æ60; 95% CI 2Æ18–33Æ95) compared with recur-
rent first trimester loss (OR 2Æ70; 95% CI 1Æ37–5Æ35) was
over threefold (Foka et al, 2000; Kupferminc et al, 2000a;
Pickering et al, 2001; Pihusch et al, 2001; Reznikoff-Etievan
et al, 2001; Carp et al, 2002; Finan et al, 2002) (Figs 4
and 5).
In contrast, acquired activated protein C resistance was
associated with a higher risk of recurrent pregnancy loss in
the first trimester (OR 2Æ60; 95% CI 1Æ21–5Æ59) than non-
recurrent loss in the second trimester (OR 1Æ59; 95% CI 0Æ19–
13Æ44) (Tal et al, 1999; Rai et al, 2001). However, the
calculated risk relating to non-recurrent second trimester
loss was non-significant and was based on data from only one
study.
Late pregnancy loss
Data relating to late pregnancy loss were extracted from 15
studies (n ¼ 4038) (Infante-Rivard et al, 1991; Bocciolone
et al, 1994; De Carolis et al, 1994; Yasuda et al, 1995;
Gris et al, 1999; Meinardi et al, 1999; Rothbart et al, 1999;
Bare et al, 2000; Kupferminc et al, 2000a; Martinelli et al,
2000; Pabinger et al, 2000; Alfirevic et al, 2001; Agorastos
et al, 2002; Alonso et al, 2002; Many et al, 2002); significant
associations were observed in carriers of heterozygous factor V
Leiden (OR 2Æ06; 95% CI 1Æ10–3Æ86), heterozygous prothrom-
bin (OR 2Æ66; 95% CI 1Æ28–5Æ53), protein S deficiency (OR
20Æ09; 95% CI 3Æ70–109Æ15) and anticardiolipin antibodies
(OR 3Æ30; 95% CI 1Æ62–6Æ70) (Fig 6). No evidence of
heterogeneity was observed.
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Fig 3. Continued.
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Pre-eclampsia
Twenty-five studies (n ¼ 11 183) assessed the risk of pre-
eclampsia in pregnancy women with thrombophilia (Yasuda
et al, 1995; Allen et al, 1996; Dizon-Townson et al, 1996;
Grandone et al, 1997b, 1999; Nagy et al, 1998; Schjetlein et al,
1998; de Groot et al, 1999; Kupferminc et al, 1999, 2000a,b;
Mello et al, 1999; O’Shaughnessy et al, 1999; Van Pampus
et al, 1999; Murphy et al, 2000; Rigo et al, 2000; Alfirevic et al,
2001; Dreyfus et al, 2001; Kim et al, 2001; Raijmakers et al,
2001; Agorastos et al, 2002; Benedetto et al, 2002; Currie
et al, 2002; D’Elia et al, 2002; Morrison et al, 2002). The risk of
pre-eclampsia was significantly associated with heterozygous
factor V Leiden (OR 2Æ19; 95% CI 1Æ46–3Æ27), heterozygous
prothrombin (OR 2Æ54; 95% CI 1Æ52–4Æ23), MTHFR homo-
zygosity (OR 1Æ37; 95% CI 1Æ07–1Æ76), anticardiolipin
antibodies (OR 2Æ73; 95% CI 1Æ65–4Æ51) and hyperhomocy-
steinaemia (OR 3Æ49; 95% CI 1Æ21–10Æ11) (Fig 7). Evidence of
Thrombophilia
n/N
No thrombophilia
n/N
OR
(95%Cl Random)
OR
(95%Cl Random)
Reduced risk
0.001 0.01 0.1 1 10 100 1000
Increased risk
* Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia.
** For the Factor V Leiden mutation, homozygous and heterozygous carriers were grouped together as it was not possible to extract data for each state.
Fig 4. Risk of recurrent first trimester pregnancy loss with thrombophilia. The square on each line represents the point estimate for the odds ratio for
each single study; its size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio and the
confidence interval from pooling all the studies together in the meta-analysis.
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heterogeneity was present in the analysis on heterozygous
factor V Leiden (P ¼ 0Æ04). The studies included in the
analysis consisted of diagnoses of both mild and severe pre-
eclampsia. Sensitivity analysis was performed by analysing the
studies reporting mild and severe pre-eclampsia independ-
ently. When restricting the analysis to mild pre-eclampsia only
(Grandone et al, 1997b, 1999; Nagy et al, 1998; de Groot et al,
1999; Mello et al, 1999; O’Shaughnessy et al, 1999; Rigo et al,
2000; Kim et al, 2001; Benedetto et al, 2002; D’Elia et al,
2002;), an OR of 2Æ30 (95% CI 1Æ27–4Æ16) was obtained, but
heterogeneity remained (P ¼ 0Æ01). However, when restricting
the analysis to severe pre-eclampsia only (Dizon-Townson
et al, 1996; Nagy et al, 1998; de Groot et al, 1999; Van Pampus
et al, 1999; Alfirevic et al, 2001), an OR of 2Æ04 (95% CI 1Æ23–
3Æ36) was obtained and evidence of heterogeneity was removed
(P ¼ 0Æ31).
Placental abruption
Seven studies (n ¼ 922) evaluated the association between
thrombophilia and placental abruption (Goddijn-Wessel et al,
1996; Owen et al, 1997; Wiener-Megnagi et al, 1998; Kupfer-
minc et al, 1999, 2000a; Alfirevic et al, 2001; Agorastos et al,
2002). Overall, thrombophilia was associated with an increased
risk of placental abruption, but significant associations were
only observed with heterozygous factor V Leiden (OR 4Æ70;
95% CI 1Æ13–19Æ59) and heterozygous prothrombin (OR 7Æ71;
95% CI 3Æ01–19Æ76) (Fig 8).
IUGR
Five studies (n ¼ 195) were included in the analysis of IUGR
(Yasuda et al, 1995; Martinelli et al, 2001b; Agorastos et al,
2002; Infante-Rivard et al, 2002; Kupferminc et al, 2002).
There was a general trend of increased IUGR risk in pregnant
women with thrombophilia; however, based on data from one
study (Yasuda et al, 1995), significant association was observed
only with anticardiolipin antibodies (OR 6Æ91; 95% CI 2Æ70–
17Æ68) (Fig 9).
Prophylactic interventions
Eight studies (n ¼ 619) evaluated the effectiveness of prophy-
lactic interventions in pregnant women with thrombophilia
(Kutteh, 1996; Kutteh & Ermel, 1996; Rai et al, 1997; Pattison
et al, 2000; Pauzner et al, 2001; Farquharson et al, 2002;
Franklin & Kutteh, 2002; Gris et al, 2004). No data on the
prevention of VTE events were found. Four of the studies
assessed the effectiveness of heparin plus aspirin versus aspirin
alone for recurrent pregnancy loss associated with antiphosp-
holipids (Kutteh, 1996; Rai et al, 1997; Farquharson et al,
2002; Franklin & Kutteh, 2002). A pooled OR of 1Æ62 (95% CI
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* Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia.
** For the Factor V Leiden mutation, homozygous and heterozygous carriers were grouped together as it was not possible to extract data for each state.
Fig 5. Risk of non-recurrent second trimester pregnancy loss with thrombophilia. The square on each line represents the point estimate for the odds
ratio for each single study; its size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio
and the confidence interval from pooling all the studies together in the meta-analysis.
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* Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia.
Fig 6. Risk of late pregnancy loss per woman with thrombophilia. FVL, factor V Leiden; PTM, prothrombin; PC, protein C; PS, protein S; ACL,
anticardiolipin antibodies; LA, lupus anticoagulant. The square on each line represents the point estimate for the odds ratio for each single study; its
size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio and the confidence interval
from pooling all the studies together in the meta-analysis.
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0Æ51–5Æ10) was estimated in favour of low-dose aspirin plus
heparin in preventing recurrent pregnancy loss. However,
minor bleeding (including haematuria, nosebleeds, gum bleeds
and bleeding at the injection site) occurred in two of the
studies and a pooled OR of 1Æ68 (95% CI 0Æ38–7Æ39) was
estimated in favour of low-dose aspirin alone (Kutteh, 1996;
Rai et al, 1997).
In one study, low-dose aspirin and LMW heparin were
compared in women with a single unexplained fetal loss from
the 10th week of pregnancy (Gris et al, 2004). Patients treated
with LMW heparin were more likely to have a healthy live birth
(OR, 15Æ5; 95% CI 7Æ0–34Æ0). Small for gestational age infants
were more frequent in patients treated with low-dose aspirin.
No other side effects of the treatment were evident in either
patients or newborns. Other studies compared the effectiveness
of low-dose aspirin versus a placebo (Pattison et al, 2000), low-
dose and high-dose heparin (Kutteh & Ermel, 1996), and
warfarin and heparin (Pauzner et al, 2001). Therefore, as the
prophylactic therapies in these studies are not comparable, the
results could not be combined in a meta-analysis.
Discussion
This is the first systematic review to present the overall
relationship between all major thrombophilias and VTE and
the adverse outcomes of pregnancy loss, pre-eclampsia, IUGR
and abruption. These data show that both heritable and
acquired thrombophilias are associated with VTE and adverse
pregnancy outcomes, so confirming and extending results
from previous systematic reviews, which have examined
particular aspects of these associations (Gates, 2000; Greer,
2003; Rey et al, 2003).
Venous thromboembolism was significantly associated with
all heritable thrombophilias except in women homozygous for
MTHFR C677T, where in contrast to the non-pregnant
situation, there was no elevation in risk. The mechanism
underlying this lack of association in pregnancy is unclear. It is
possible that folic acid supplements taken in pregnancy could
reduce homocysteine levels in these women and so reduce the
risk of VTE, but there is minimal data on the use of vitamin
supplements in the studies reported and this possibility could
not be examined with the available data. The risk of VTE with
homozygous factor V Leiden was the highest risk observed for
any thrombophilia, with a relative risk of 34Æ4 (95% CI 9Æ86–
120Æ05), reducing to 8Æ32 (95% CI 5Æ44–12Æ70) with heterozy-
gous factor V Leiden. While these are significant increases in
relative risk, the absolute risk remains modest. For example,
the underlying incidence of VTE in pregnancy is considered to
be around 1:1000. Thus, these relative risks translate to
absolute risks of 3Æ4% and 0Æ8% respectively. Of note, women
Reduced risk
0.001 0.01 0.1 1 10 100 1000
Increased risk
* Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia.
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Fig 6. Continued.
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Fig 7. Risk of pre-eclampsia in women with thrombophilia. The square on each line represents the point estimate for the odds ratio for each single
study; its size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio and the confidence
interval from pooling all the studies together in the meta-analysis.
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heterozygous for factor V Leiden and homozygous for
prothrombin G20201A were judged to be at a higher risk of
VTE than any other pregnancy complication studied. No
studies were found that measured the risk of pregnancy-related
VTE in women with elevated anticardiolipin antibodies, lupus
anticoagulants or acquired activated protein C resistance,
therefore, the risk of VTE in pregnancy with acquired
thrombophilia remains unclear. Furthermore, the risk of
DVT and PE could not be established separately as all studies
measured VTE as a single outcome.
Of the inherited thrombophilias, only women homozygous
for factor V Leiden or heterozygous for prothrombin G20210A
had a significant association with early loss. Women homo-
zygous for factor V Leiden or with hyperhomocysteinaemia
were at a significantly higher risk of suffering an early
pregnancy loss compared to women with other thrombophi-
lias. Moreover, the risk of early pregnancy loss with hype-
rhomocysteinaemia was greater than the risk of any other
pregnancy complication with this condition. The acquired
thrombophilias, including elevated anticardiolipin antibodies,
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Fig 7. Continued.
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* Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia.
Fig 8. Risk of placental abruption in women with thrombophilia. The square on each line represents the point estimate for the odds ratio for each
single study; its size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio and the
confidence interval from pooling all the studies together in the meta-analysis.
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lupus anticoagulants and acquired activated protein C resist-
ance, were also significantly associated with pregnancy loss
before 24-week gestation. The magnitude of risk was modest;
however, early pregnancy loss is a very heterogeneous condi-
tion and only a proportion of these losses will be related to
thrombophilia. A stronger association was found with recur-
rent miscarriage, which is likely to be more specific for an
underlying thrombophilia. When early pregnancy loss was
classified according to recurrent loss in the first trimester and
non-recurrent loss in the second trimester, a higher risk of
second trimester loss for both factor V Leiden and prothrom-
bin G20210A heterozygotes was calculated. This is consistent
with a recent analysis on thrombophilia and recurrent
pregnancy loss (Rey et al, 2003). Although there were insuf-
ficient data to ascertain the risk of second trimester pregnancy
loss with lupus anticoagulants, the risk of recurrent first
trimester pregnancy loss was higher than for any other
pregnancy complication with this acquired thrombophilia.
Of all thrombophilias, late pregnancy loss was most strongly
associated with protein S deficiency. Women heterozygous for
either factor V Leiden or prothrombin G20210A or with lupus
anticoagulants were also at significantly increased risk of loss
beyond 24-week gestation. The remaining thrombophilias
studied were not significantly associated with late loss. These
findings are consistent with another systematic review (Alfir-
evic et al, 2002), which established that women with protein S
deficiency were at the highest risk of unexplained stillbirth
after 20 weeks.
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* Data was only available for one study, therefore meta-analysis was not carried out for this thrombophilia.
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Fig 9. Risk of intrauterine growth restriction in women with thrombophilia. The square on each line represents the point estimate for the odds ratio
for each single study; its size of the square varies according to study size and variance. Black diamonds represent the overall average odds ratio and the
confidence interval from pooling all the studies together in the meta-analysis.
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In comparing early pregnancy loss before 24 weeks and late
loss beyond this stage of gestation, we found that in women
heterozygous for factor V Leiden or prothrombin G20210A,
the risk of late pregnancy loss was higher than that for early
loss. These findings are consistent with another systematic
review on heritable thrombophilia and fetal loss (Rey et al,
2003), who also found a significant association between factor
V Leiden and fetal loss, the association being more robust if
fetal loss arose after 19-week gestation. Our results for acquired
thrombophilias indicated that elevated anticardiolipin anti-
bodies and lupus anticardiolipins were associated with higher
risk of early pregnancy loss. Studies that did not specify the
timing of pregnancy loss were excluded from the review. Data
from these studies were pooled together to examine whether
including these studies would have influenced the final results.
The results from the 12 studies showed that factor V Leiden
and prothrombin G20210A were associated with pregnancy
loss. Therefore, as these results were obtained before exclusion
of these studies, it is unlikely that excluding these studies
would influence the final results.
With regard to pre-eclampsia, significant associations with
hyperhomocysteinaemia, elevated anticardiolipin antibodies,
heterozygosity for factor V Leiden and prothrombin G20210A
were found. Pre-eclampsia was the only outcome for which a
significant association with homozygosity for MTHFR C677T
was found. The increase in risk of pre-eclampsia with
thrombophilia is modest. Thrombophilia may contribute to
the severity of pre-eclampsia because of an exaggerated effect
of the disorder on the haemostatic system in women with
thrombophilia (Morrison et al, 2002). The highest risk of
placental abruption was in women heterozygous for pro-
thrombin G20210A, followed by heterozygous factor V Leiden
and hyperhomocysteinaemia. These results are similar to those
established by other systematic reviews (Gates, 2000; Alfirevic
et al, 2002). In IUGR, the highest risk was in women
homozygous for factor V Leiden, followed by heterozygotes
for prothrombin G20210A. Alfirevic et al (2002) concluded
that pregnant women with elevated anticardiolipin antibodies
and protein S deficiency were at highest risk of IUGR.
However, their findings were based on only three studies
involving very small numbers of women. Additionally, they did
not use a prespecified definition of IUGR.
Studies measuring the effectiveness of prophylactic inter-
ventions were lacking, in keeping with the findings of the
Cochrane review on this area, which included data published
up to 2003 (Walker et al, 2005). It remains to be established
whether intervention with LMW heparin is of benefit in
women with thrombophilia and an underlying pregnancy
complication. Further randomised controlled trials are needed
to explore this possibility. Other studies included compared
different treatments; therefore, it was not possible to group
these studies together. Several studies measured the effective-
ness of plaquinil in treating pregnancy-related VTE. This drug
is no longer used in clinical practice and as these findings are
irrelevant, they were not included in this review.
Systematic reviews have several limitations, including selec-
tion bias and varying methodological quality of studies. All
studies included in this review were independently judged as
moderate to high quality using a standardised checklist.
Laboratory methods for individual studies used standardised
techniques and specific cut-off values to identify thrombophilia.
Furthermore, testing for deficiencies of antithrombin, protein C
and protein S was performed at least 6 weeks after pregnancy in
all studies. Publication bias can arise in systematic reviews. We
restricted this review to studies that were published in English. It
is well understood that in the field of obstetrics and gynaecology,
good quality studies are published in English (Egger et al, 2003).
Therefore, it is believed that excluding non-English studies
would make no significant difference to the results.
Due to the fact that not all studies tested for all major
thrombophilias, we cannot eliminate the possibility that some
control women without the thrombophilia studied were
carriers of thrombophilias that were not tested for. This
possibility could lead to underestimation of the association
between thrombophilia and the adverse outcomes studied.
Additionally, it is clear for VTE that individuals from
symptomatic thrombophilic kindred differ in risk from
unselected individuals or those from asymptomatic kindred
with the same thrombophilic genotype. This is likely to be due
to an additional (often unidentified) defect or interaction.
While this is clear for thrombosis, we have little information of
this in pregnancy complications, but it remains likely that the
same or similar factors could operate.
Despite strict inclusion criteria, there were instances of
interstudy heterogeneity. A possible explanation for such
heterogeneity is genetic variations between ethnic populations
studied. The studies included in the review were conducted
among participants of different ethnic backgrounds. Throm-
bophilia defects are known to vary according to race, in
particular, thrombophilia is more prevalent in Caucasians
(Franco et al, 1998; Rosendaal et al, 1998). This is supported
by a study included in this review, where a higher OR was
obtained when analysis was restricted to white women only
(Dilley et al, 2000). Another factor that could contribute to the
heterogeneous results was different sensitivity and specificity of
the laboratory methods used in testing for thrombophilia.
An often overlooked area is the risk of VTE associated with
ovarian stimulation for assisted conception therapy, where
women are exposed not only to the pregnancy-associated risks
of VTE but also the effects of hyperestrogenism. Hyperstim-
ulation is associated with procoagulant changes in the haemo-
static and fibrinolytic systems and increased risk of venous and
arterial thrombosis, although the overall rate of thrombosis in
assisted conception is low (Gompel et al, 2002). Women with
thrombophilia may be at particular risk, and jugular vein
thrombosis has been reported following in vitro fertilisation in a
compound heterozygote for protein S deficiency and pro-
thrombin G20210A despite therapeutic anticoagulation with a
LMW heparin (Reid & Perry, 2001). Thus, in view of the
established risk of VTE with thrombophilia in pregnancy,
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women with possible thrombophilia undergoing assisted con-
ception therapy require special consideration with regard to
their risk of thrombosis and need for prophylaxis.
Conclusions
Recent debate has focused on whether universal screening for
thrombophilia should be performed prior to pregnancy. Our
review has confirmed that women with thrombophilia are at
increased risk of developing complications during pregnancy.
However, despite the increase in relative risk, the absolute risk
of VTE and adverse outcomes in pregnancy remains low.
Furthermore, aside from recurrent pregnancy loss in anti-
phospholipid syndrome and prevention of VTE, there is
insufficient evidence on the benefit of antithrombotic inter-
ventions to guide therapy. While there is recent evidence
suggesting this possibility in adverse pregnancy outcomes
(Brenner et al, 2005), benefit cannot be concluded in the
absence of controlled clinical trials. Such trials are urgently
required. Thus, at present, universal screening for thrombo-
philia in pregnancy cannot be justified clinically.
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